Latest guidance  

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues
Supporting adult carers
Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Latest guidance in consultation  

Esketamine for treatment-resistant depression (ID1414)
Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer [ID1338]
Liraglutide for managing overweight and obesity [ID740]
Faltering growth
Behaviour change: digital and mobile health interventions

Explore NICE

  1. News|
  2. About|
  3. Events|
  4. Get involved

Latest news  

  1. Nasal spray medicine for treatment-resistant depression not recommended by NICE
  2. Digital and mobile interventions could support regular health services in helping people stop smoking and reduce their risk of obesity, says NICE
  3. NICE encourages further data collection on ‘game changing’ histology independent cancer drugs
  4. Make use of community pharmacists’ skills, says NICE

Tweets

by @NICEcomms